New York, NY. Authenticity. It’s what our customers want from us. And, turns out, it’s what patient advocacy groups want from pharma, too. Yesterday, inVentiv Health’s Public Relations Group released a report, “The New Partnership Paradigm: What Patient Advocates Seek from Pharmaceutical Partners.” And, number one on the patient advocacy wish list: improve transparency and authenticity.

Patient advocacy groups and pharma have historically had a mutually beneficial relationship. Patient advocacy groups hold access to patients and insights, while pharma provides the resources for current support and the hope for future treatments.

According to the report, this relationship is expected to strengthen. Patient advocate groups want to be more active in the design and execution of clinical trials. They want to be involved in awareness and education campaigns for patients, healthcare providers and caregivers. It’s fitting because these are activities that will advance their mission.

On the flip side, pharma is faced with access issues and drugs that are becoming prohibitively expensive for patients, which better aligns them with patient advocacy groups that are already working for this cause politically. In addition, the growing pipeline of rare disease treatments will result in many brands seeking highly specific patient populations for trials and behavioral insights, to which patient advocacy groups hold the key.

As the relationship between patient advocacy groups and pharma gets even stronger, how can we deliver on the ask for transparency and authenticity?

They want a real commitment

“A year or two before their medication heads to generic status, the companies too often pull back from their support of the community, says Elizabeth “Eli” Pollard, executive director of the World Parkinson Coalition. In doing so, companies haven’t fulfilled their commitment to treat advocacy groups as true partners.”

They want to be consulted as experts in a therapeutic category

“The groups and their networks of volunteers know the doctors best able to treat an illness. They keep up with the research.”

They want to connect us with patients

Some patient organizations complain that social channels give pharmaceutical company funders a false sense of intimacy with patients and their support and service groups. “If pharma is going to enter into a disease space, they need to be open to hearing directly from patients,” says Christine S. Brown, executive director of the National PKU Alliance.“ They need to hear [patients’] stories and connect with them.”

They want us to keep them informed

Some advocates fault drug companies for failing to take advantage of new communication channels to provide timely clinical or pricing information on their products. Instead, drug makers often hold patient organizations at arm’s length — the opposite of what healthcare consumers expect in the age of Facebook and PatientsLikeMe.

For more insights, see the full report from inVentiv Health’s Public Relations Group.

About the Author:

As Managing Director of Innovation and Insights for Syneos Health Communications, Leigh is responsible for building and scaling a global team of healthcare experts who together help life science leaders better understand the complex lives, influences and expectations of their customers. Specifically, they uncover actionable insights that fuel empathy and creativity; lead co-creation events that let marketers learn from peers, trends, and new possibilities; and help clients identify the most valuable and useful new customer experiences to create.

Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for nearly 20 years.She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she held several leadership roles at our largest agency, GSW.  There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business.

Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes.

A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. This year, she led over 250 experts to experts to focus on the most important changes in the commercial, consumer, marketing, digital and healthcare landscapes. (See reports at

Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice and Top 10 Innovation Catalysts of 2017 by MM&M, Leigh also was recognized  as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.